SOURCE: Sanguine Corporation

September 17, 2008 06:00 ET

Sanguine Corporation Announces Additional Business Directives

PASADENA, CA--(Marketwire - September 17, 2008) - Sanguine Corporation (OTCBB: SGUI) is pleased to announce additional business directives aimed at focusing its PHER-O2 development objectives in other areas outside of synthetic blood. According to David Nelson, Sanguine's CFO, Sanguine has decided to target its primary efforts in three promising markets that it believes represent a much clearer path toward success.

Nelson added, "Over the past 12 months we have been working diligently to better position the Company and to move its core business forward. As part of our plan, management sought out a more diversified approach to its business model. In conjunction with outside researchers and companies, pending successful testing programs, we are planning to use PHER-O2 in the areas of MRIs, organ transport and wound care. Management believes these areas could significantly enhance partnership initiatives currently underway. Partnership and/or licensing opportunities currently under review in the above named areas potentially provide Sanguine with revenue generation at a much earlier stage. As part of Sanguine's commitment to its shareholders, we made the decision to seek out partners to help subsidize development costs and expedite time to market for PHER-O2. In addition, Sanguine, through our subsidiary Sanguine Life Sciences, has made progress in locating further opportunities that may help serve the Company's future overall business objectives."

About Sanguine Corporation:

Sanguine Corporation is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of perfluorocarbon-emulsion based oxygen carriers. The Company has under development testing programs in areas where synthetic oxygen and/or gas profusion is important such as medical imaging, wound care and transplant tissue transportation. These products are based upon core technologies that include biomedical applications for perfluorocarbon-emulsions and medical and other non-medically therapeutic applications for biosensors. The Company's product, PHER-O2 is designed with advantages over currently marketed products in major markets including magnetic resonance imaging, stroke, surgery, trauma, malignant tumors, wound care and diabetes.

For information related to the Sanguine Corporation, contact Investor Relations: Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit: www.sanguine-corp.com.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

Contact Information

  • Contact:
    For Sanguine Corporation
    Michael Dancy
    801-746-3570
    (Investor Relations)
    Email Contact